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Objectives: The potential for synergy between colistin and fusidic acid in the treatment of MDR Acinetobacter
baumannii has recently been shown. The aim of this study was to perform an extensive in vitro characterization
of this effect using pharmacokinetic-pharmacodynamic modelling (PKPD) of time–kill experiments in order to es-
timate clinical efficacy.
Methods: For six clinical strains, 312 individual time–kill experiments were performed including 113 unique
pathogen–antimicrobial combinations. A wide range of concentrations (0.25–8192 mg/L for colistin and
1–8192 mg/L for fusidic acid) were explored, alone and in combination. PKPD modelling sought to quantify syner-
gistic effects.
Results: A PKPD model confirmed synergy in that colistin EC50 was found to decrease by 83% in the presence of
fusidic acid, and fusidic acid maximum increase in killing rate (Emax) also increased 58% in the presence of colistin.
Simulations indicated, however, that at clinically achievable free concentrations, the combination may be bac-
teriostatic in colistin-susceptible strains, but growth inhibition probability was,20% in a colistin-resistant strain.
Conclusions: Fusidic acid may be a useful agent to add to colistin in a multidrug combination for MDR
Acinetobacter baumannii.
Introduction
The rise of antimicrobial resistance has captured global attention
with particular focus on MDR infections for which viable therapeutic
options range from few to none.1 MDR Acinetobacter baumannii
(MDRAB) is a prime example of a threat to modern medicine, with its
predilection for the critically ill, affecting the success and progress of
a wide range of medical fields including surgery and oncology.2
Colistin, first discovered in the 1940s and subsequently aban-
doned in clinical use for less toxic alternatives, is now increasingly
used as an agent of last resort to combat MDR Gram-negative
infections.3 In attempts to preserve the usefulness of colistin clinic-
ally, researchers have been investigating its use in combination
with other licensed antimicrobial agents.4 This approach appears
to present a number of advantages: relative increase in antimicro-
bial activity of the combination; potential reduction of the dose of
colistin (thereby minimizing toxicity); retardation of the develop-
ment of resistance; and enhancement of bactericidal activity and
hence a cure for an infection that might not otherwise be curable
with current monotherapies.4 Moreover, there have been reports
of rapid evolution of colistin resistance during colistin monother-
apy resulting in therapeutic failure.4–6 Colistin heteroresistance is a
well-described phenomenon amongst A. baumannii isolates and
has been thought to contribute to therapeutic failure with mono-
therapy, as heteroresistant isolates may appear to be susceptible
to colistin in vitro by conventional susceptibility testing methods
used in routine clinical laboratories (e.g. broth microtitre dilution).
In an effort to investigate colistin susceptibility, as well as incorpor-
ate clinical dosing regimens to better predict clinical outcome,
pharmacometric modelling on time-course experiments has been
developed and explored in recent years.7–9
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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A systematic review by Zusman et al.10 has concluded that cur-
rent evidence does not advocate for the use of previously
described colistin combinations (e.g. colistin/rifampicin and colis-
tin/tigecycline) despite synergy in vitro cited by many sources.4,11
More recently, Paul et al.12 concluded that there was a lack of evi-
dence for the addition of meropenem to colistin for the treatment
of carbapenem-resistant A. baumannii based on a large multi-
centre randomized controlled trial. This is in stark contrast to a
meta-analysis of in vitro studies of polymyxin/carbapenem combi-
nations by Zusman et al.13 citing strong synergistic antibacterial ef-
fect. This might be due, in part, to the overly simplistic way in
which synergy is defined. Most commonly, chequerboard assays,
which are based on determinations of MIC with or without expos-
ure to the second agent,14,15 are used. Although synergy in cheq-
uerboards may indicate a useful mechanism, ensuring this effect
persists at clinically achievable concentrations is crucial to predict-
ing clinical utility.
Pharmacokinetic-pharmacodynamic (PKPD) modelling of in vitro
experiments may better describe the interaction between two
agents over time compared with chequerboard experiments,
hence improving the prediction of their combined antimicrobial ac-
tivity.16–19 Rao et al.18 described the lack of sustained synergy,
which was observed initially between polymyxin B and tigecycline,
when using current recommended doses. Modelling the time–kill
curves provided possibilities for optimizing antibacterial activity by
increasing doses of tigecycline and/or including a loading dose for
polymyxin B.18
The aim of this study was to model time–kill experiments, to
better understand the synergy we have previously observed be-
tween colistin and fusidic acid against A. baumannii20 using con-
ventional methods of assessing synergy (i.e. chequerboards and
time–kill experiments utilizing NCCLS definitions).21 In particular,
the model seeks to address differences between antimicrobial ac-
tivity of the combination against strains exhibiting high-level colis-
tin resistance (MIC .256 mg/L) compared with heteroresistant
strains. We then assessed the potential for in vitro synergy to
translate into clinical dose recommendations using Monte Carlo
simulation.
Methods
Bacterial strains
Six A. baumannii strains were selected to be included in the study: ATCC
19606 (antibiotic-susceptible type strain) and five MDR clinical isolates rep-
resenting OXA-23 UK clone I (AB14 and AB315), OXA-23 UK clone II (AB16),
SE clone (AB12) and a colistin-resistant strain (AB205) (isolates and typing
information provided by J. Turton, Public Health England). Broth microtitre
dilution colistin MICs were 0.25 mg/L for ATCC 19606; 0.5 mg/L for AB14 and
AB16; 1 mg/L for AB12 and AB315; and .256 mg/L for AB205. Broth micro-
titre dilution fusidic acid MICs were 32 mg/L for AB205; 64 mg/L for AB12;
128 mg/L for AB14 and ATCC 19606; 256 mg/L for AB315; and 512 mg/L for
AB16. All isolates were stored at#70C and grown on unsupplemented Iso-
Sensitest agar (ISA; Oxoid, Basingstoke, UK) under aerobic conditions at 37C.
Antibiotics
Stock solutions of colistin sulphate (Alfa Aesar, Haverhill, USA) and fusi-
dic acid (Sigma–Aldrich, St Louis, USA) were prepared with sterile dis-
tilled water to yield concentrations of 10 000 mg/L and 50 000 mg/L
respectively.
Time–kill assays
Overnight broth cultures of each isolate were prepared in 10 mL of Iso-
Sensitest broth (ISB; Oxoid). Time–kill assays were set up in 10 mL ISB with
starting inocula of 106 cfu/mL as per a previously published protocol.20 A
separate experiment to investigate inoculum effect with AB14 was con-
ducted using starting inocula ranging between 107 and 108 cfu/mL.
Concentrations of colistin used ranged from 0.25 to 8192 mg/L (colistin
concentrations 1024–8192 mg/L were prepared directly in broth without
the use of antibiotic stock solution) and fusidic acid concentrations from 1
to 8192 mg/L. Concentrations chosen ranged from suboptimal to maximal
(or 8192 mg/L) bactericidal activity for each single- or dual-agent condition.
Bacterial colony counts were determined by plating out 100lL aliquots
(with serial dilutions in sterile PBS where appropriate) onto unsupple-
mented Iso-Sensitest Agar (ISA), with manual counts performed following
incubation under aerobic conditions at 37C for 18–24 h.
LC-MS/MS analysis
Simulated samples were prepared in parallel to investigate the changes to
concentrations of colistin and fusidic acid with time, singly and in
combination.
Samples and calibration standards were filtered using a Millex 0.22lM
low-binding fast-flow variety Polyethersulfone (PES) membrane filter unit.
The filtrates were then extracted by protein precipitation [50lL of
sample!250lL of acetonitrile:water (70:30) containing 100 ng/mL of in-
ternal standard]. Samples were centrifuged at 13 000 rpm for 10 min in a
microfuge. One hundred microlitres of supernatant was transferred into a
96-well plate for sample analysis.
Samples and calibration standards were analysed by LC-MS/MS. An
Acquity BEH Protein C4 1.7lm 2.1 mm%100 mm column was used for the
analysis. Reversed-phase gradient chromatography was performed with
0.1% formic acid in 100% water (A) and 0.1% formic acid in 100% aceto-
nitrile (B) at a flow rate of 0.4 mL/min. The gradient used was 0 min, 5% B;
4.50–4.70 min, 95% B; 4.80 min, 5% B; 5.30 min, stop. The injection volume
was 5lL.
Positive/negative ion-switching electrospray tandem mass spectrom-
etry was performed using a Sciex API 6500 QTRAP mass spectrometer with
multiple reaction monitoring (MRM) detection mode (controlled by Analyst
1.6.2 software). The ion spray voltage was set to 4000 V (+switching) and
the probe temperature was set at 500C. Nitrogen was used as the collision
gas. The nebulizer gas (GS1), curtain gas and turbo gas (GS2) were set to 55,
40 and 55 psi, respectively. MRM parameters used are shown in Table 1. A
10 ms dwell time was used between each MRM.
Modelling
Concentration and cfu data transformed into their natural logarithm and
logarithm base 10, respectively, were modelled using NONMEM 7.3 on a
Windows 10 operating system. Minus twice the log likelihood of the data
was used as objective function value (OFV). A drop in OFV of at least 3.84
Table 1. MRM parameters used for colistin A, colistin B and fusidic acid
assays
Compound MRM (m/z) DP (V) CE (V) CXP (V)
Colistin A 585.4/241 156 29 12
Colistin B 578.7/227.2 151 29 22
Fusidic acid 515.3/221.0 #130 #36 #10
DP is the declustering potential, CE is the collision energy and CXP is the
collision cell exit potential.
Phee et al.
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points (P"0.05) after inclusion of one additional parameter (one degree of
freedom) to a nested hierarchical model was considered to statistically im-
prove the model’s ability to describe the data. Discrimination of hierarchical
models was further supported by goodness-of-fit diagnostics and biological
plausibility.
Colistin and fusidic acid concentration data were estimated using
ADVAN9 and the FOCE-I estimation method. A. baumannii cfu data were
estimated using ADVAN9 and the Laplacian estimation method in order to
facilitate the use of the so-called ‘M3 method’ for including cfu counts
below 10 cfu/mL.
Dynamic colistin and fusidic acid drug concentrations in broth over time
were modelled to study drug degradation and/or binding within the time
span of the in vitro static time–kill curve experiments (i.e. 24 h). Baseline
concentrations were fixed to the observed value with an added residual
error term of the same magnitude as the residual variability (Eq. 1).
Pi ¼ hBL  ee (1)
Pi represents estimated individual baseline concentration by hBL, which was
fixed to the observed baseline, with  being the proportional residual error
(additive on the log scale).
Drug degradation was described using a first-order process (Eq. 2).
dC
dt
¼ hk  C (2)
Changes in drug concentration (C) over time (t) in Eq. 2 were explained by a
rate constant (hk) and drug concentrations.
A. baumannii baseline cfu was evaluated using both observed and esti-
mated (Eq. 1) initial conditions. Bacterial growth was described using a lo-
gistic model (Eq. 3) with lag time (Eq. 4).
dcfu
dt
¼ k cfu  1 cfu
hcfumax
 !
(3)
k ¼ hnet þ 2 hnet t
20
hlag
20 þ t20
 !
(4)
The rate constant k (Eqs. 3 and 4) represents the net growth and hcfumax
(Eq. 3) is the maximum carrying capacity. The underlying net growth in Eq. 4
is described by hnet and the time where half of the maximum lag time
occurs is described by hlag.
The growth model was developed on antimicrobial-free data only.
Growth parameters were subsequently fixed and used to estimate cfu data
for AB14 strain A. baumannii exposed to a range of colistin or fusidic acid
concentrations. Drug effects were described using a sigmoidal Emax model
(Eq. 5) and a time-dependent drug effect component, representing the de-
velopment of resistance, which was described using a Gompertz model.
E ¼ hEmax  C
hc
hhcEC50 þ C
hc
1  hb 1 et hsCð Þð Þ
 
(5)
C in Eq. 5 represents drug concentration; the drug effect (E) in Eq. 5 was
described by the maximum drug effect (hEmax), the concentration realizing
half the maximum effect (hEC50) and a shape parameter (hc). The effect size
of time-dependent drug effect was represented by hb (which was con-
strained to take values in the interval 0 to 1) in Eq. 5, the duration of the
treatment effect was described by hs and drug concentrations were repre-
sented by C. The basic model for change in cfu with time was therefore
given by:
dcfu
dt
¼ k Eð Þ  cfu 1 cfu
hcfumax
 !
(6)
The terms in E were further refined as follows: hb in the Gompertz time-
dependent drug effect component was fixed for fusidic acid and drug com-
binations to the estimated value for colistin. Both static drug concentrations
as well as dynamic drug concentrations, adjusted for drug degradation,
were evaluated.
Bacterial burden (cfu) over time data from the ATCC 19606, AB12, AB16,
AB315 and AB205 A. baumannii strains were sequentially included into the
model. Altered drug susceptibility for each A. baumannii strain was
assessed as categorical covariates (Eq. 7) with stepwise-covariate model
building on Emax, EC50, c, b and s.
Covariate ¼ ð1 þ hcovÞ (7)
The hcov in Eq. 7 represents the effect size of the categorical covariate.
Emax and time-dependent drug effect parameters (i.e. drug resistance
development parameters) were fixed for colistin and fusidic acid and used
to estimate cfu data for AB14 A. baumannii exposed to the colistin and fusi-
dic acid drug combination at a range of concentrations. An additive colistin
and fusidic acid drug effect was used as starting point. A categorical covari-
ate (Eq. 7) on b for drug combinations was embedded in the model.
Time–dependent effect ¼
1 hbð1 etððhscolCcolÞþðhsfusCfusÞþðhscombCcolCfusÞÞÞ
(8)
The effect size of time-dependent drug effect was represented by hb in
Eq. 8, the duration of the colistin (col), fusidic acid (fus), and combination
(comb) treatment effect was described by hs and corresponding drug con-
centrations were represented by C. This term was multiplied by the effect
parameter, and hence effect decreases to 0 with increasing time and
concentration.
Subsequently, colistin and fusidic acid interaction effects were assessed
with stepwise-covariate model building using categorical covariate rela-
tions (Eq. 7) or an Emax model (Eq. 5), without Emax and c estimated, on
Emax, EC50, c, b and scomb.
cfu-over-time data from the ATCC 19606, AB12, AB205, AB315 and
AB16 A. baumannii strains were sequentially included into the model.
A non-parametric bootstrap (n"1000) was performed in order to de-
rive the parameter standard errors. The prediction-corrected visual predict-
ive check (VPC) enabled the assessment of the model’s predictive
performance. The 5th, 50th and 95th percentiles of the observed data were
overlaid with the 95% CIs of the simulated (n"2000) 5th, 50th and 95th
percentiles of the data for drug concentrations.
Simulations
Clinical PK models were identified for intravenous colistin (given as its pro-
drug, colistimethate sodium) and oral fusidic acid and used to simulate
concentration–time profiles under standard and high dosing regimens.22,23
For intravenous colistimethate sodium therapy, standard dosing was set to
2 million units (MU) three times per day, and high dosing was a loading
dose of 9 MU followed by 3 MU three times per day.23 For oral fusidic acid
therapy, standard dosing was defined as 500 mg three times per day, with
high dosing defined as a loading dose of 1500 mg followed by 750 mg three
times per day. Simulations (n"1000) of free drug, assuming an unbound
fraction of 64% and 10% for colistin and fusidic acid respectively, were
applied to the final model, giving a predicted change in cfu/mL at 24 h.
Comparison of the log10 decrease in cfu/mL under standard and high
Colistin/fusidic acid for Acinetobacter JAC
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dosing was made for colistin or fusidic acid alone or the combination
was made.
Results
Drug degradation experiments
Colistin and fusidic acid concentrations by LC-MS/MS were
obtained for 103 simulated aliquots, ranging from 0 to 4 mg/L for
colistin and 0 to 64 mg/L for fusidic acid, either singly or in combin-
ation, at timepoints 0, 2, 6 or 24 h.
Although fusidic acid concentrations remained constant, colistin dis-
played drug degradation and/or binding within the time span of the 24h
in vitro static time–kill curve experiments at a rate of 0.0175h#1 [relative
standard error (RSE): 20.9%] (Figure 1). In general, the model displayed
good predictive performance for both colistin and fusidic acid (Figure 1).
Colistin drug degradation did not contribute to a significantly
improved description of the A. baumannii cfu data (P.0.05) and
was ultimately not included in the model.
Time–kill experiments
Three hundred and twelve individual time–kill curves were included
in the model, including 114 unique pathogen–antimicrobial combi-
nations (27 colistin only, 33 fusidic acid only, 54 colistin/fusidic acid
conditions) (see Supplementary Figures S1 to S4, available as
Supplementary data at JAC Online). Eight high-inoculum experi-
ments were performed in triplicate with no obvious inoculum effect
on model fit (Figures S5 to S8).
The A. baumannii cfu growth model fit was improved by the in-
clusion of a lag time (DOFV"#5.52; P,0.05) and was able to ac-
curately and precisely describe the observed A. baumannii cfu
growth data (Figure 2).
Both the colistin drug effect and fusidic acid drug effect were
predicted well by the model (Figure 2). AB205 was substantially
less susceptible to colistin (65.2-fold increase in EC50col) and more
susceptible to fusidic acid (2.12-fold increase and#0.124-fold de-
crease in hsfus and hbfus, respectively) (Table 2).
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Figure 1. Basic goodness-of-fit and VPC plots for fusidic acid concentrations (left) and colistin concentrations (right). Top row: observed concentration
(OBS) versus population prediction (PPRED) with line of unity and a dashed black line representing a smooth, and dashed grey line joining points from
the same experiment. Second row: conditional weighted residuals (CWRES) versus PPRED, with and a dashed black line representing a smooth, a
dashed grey line joining points from the same experiment and a black dotted line representing the expected 95% interval of the standard normal dis-
tribution. Bottom row: VPCs for fusidic acid concentrations (left) and colistin concentrations (right). The dashed and solid lines represent the 5th and
95th percentiles and the 50th percentile of the observed (black dots) concentration data, respectively.
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In general, the model provided a good description of the cfu
data, and simulated trends match those observed (Figure 2).
Moreover, the individual prediction versus observed cfu plots and
individual model-predicted trajectories over time, stratified by
treatment combination, indicate that the majority of the data are
reasonably well described. There was substantial interaction be-
tween colistin and fusidic acid, with fusidic acid reducing EC50col by
82.6% and colistin increasing Emaxfus by 57.9% (Table 2). AB12 dis-
played a decreased colistin/fusidic acid combination resistance
(Table 2). Simulations of probability of the degree of 24 h cfu de-
crease are given in Figure 3.
Discussion
MDR Gram-negative infections, for which therapeutic options are
rapidly dwindling, are a current problem requiring urgent atten-
tion.24,25 One of the most successful Gram-negative organisms to
date is A. baumannii; its success is due to its ability to acquire and
express phenotypic resistance to multiple classes of antibiotics, its
resistance to numerous biocides and persistence on fomites, and
its ability to cause a diverse range of infections, particularly in the
critically ill population.26–28 Unfortunately, MDRAB has become a
common infection globally, to which only agents of last resort (e.g.
polymyxins and tigecycline), if any, may retain activity. Fear of
therapeutic failures on polymyxin monotherapy has led to clini-
cians employing a range of combination therapies. Colistin, which
is the predominantly used polymyxin, has seen a renaissance, with
numerous reports in literature of its use with a range of other anti-
microbial agents, often broad spectrum, with varying results.11 Our
major finding is that although the addition of fusidic acid improves
the bacterial killing rate, the double combination is insufficient for
sustained bacteriostatic activity at clinically achievable
concentrations.
The prevailing methods of investigating synergy between anti-
microbial combinations do not sufficiently describe the antibacterial
effect, and this may underlie the discrepancies observed between
in vitro observations and clinical efficacy.29,30 Methodologies, such
as chequerboard assays, although attractive for screening large
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Figure 2. Top row: observed (Obs) versus population-predicted (PPRED) Acinetobacter baumannii cfu (left) and conditional weighted residuals
(CWRES) versus PPRED (right) for the model with colistin and fusidic acid drug effect. The grey circles represent observed data, black dashed lines rep-
resent the locally estimated scatterplot smoothing (LOESS) trend lines, the black lines represent the lines of identity and dotted lines represent the
95% CI. Middle row: prediction-corrected VPC for Acinetobacter baumannii cfu growth (left) and colistin drug effect (right) model. Bottom row: prediction-
corrected VPCs for Acinetobacter baumannii cfu fusidic acid drug effect (left) and colistin and fusidic acid drug effect (right) model. The black dots repre-
sent observations and the dashed and solid lines in the VPCs represent the mean 5th, 50th and 95th percentiles of the simulated (n"2000) data.
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numbers of combinations, may be inferior to time-course methods,
as analysis of drug interaction and the consequent antibacterial ef-
fect is based on a single endpoint result. Moreover, these results do
not provide any information regarding bactericidal activity, which is
an important factor for accurate prediction of clinical efficacy.20,31
Dynamic models are extremely labour intensive32 and thus
limit the number of different conditions (i.e. concentrations of
each agent, either singly or in combination) one can input into the
model, decreasing the accuracy of the model. Static time–kill
assays were chosen [with modelling of concentrations of both
drugs singly and in combination via an LC-MS/MS method to take
into account the natural attrition of the drug(s) over 24 h] as a
compromise to assess the novel antibiotic combination, colistin/
fusidic acid. We have previously published data on the synergy
observed against A. baumannii (including MDR and XDR strains)
using chequerboard assays and time–kill assays employing the
NCCLS definition (i.e. 2 log10 cfu/mL decrease in bacterial colony
count at 24 h in the combination arm compared with either single
agent), as well as the relative reduction in mutational resistance
in vitro in the combination arm compared with single-agent expos-
ure.20 Here, we utilized a modelling approach to describe the syn-
ergistic effect of the colistin/fusidic acid combination and,
importantly, using simulation to give a probability of success
(Figure 3).
We conducted most experiments on AB14 (typical clinical strain
in the UK, OXA-23 UK clone I), and therefore colistin, fusidic acid
and the colistin/fusidic acid drug combination effect models were
initially developed using this strain. The drug effect model was
developed by sequentially including colistin, fusidic acid and colis-
tin/fusidic acid time–kill data. Simultaneous estimation of all
model parameter estimates with the final model gave conver-
gence problems and hence parameters were fixed in a stepwise
fashion from a drug-free model, to individual colistin and fusidic
acid effect, through to the combination model. This meant that
model misspecification arising from our simple model could not
bias parameter estimates of drug-free and single drug experi-
ments when adding the combination data, although it may inflate
unexplained variability. This approach yielded a good fit to the
data (Figure 2) and a recent study highlighting mathematical iden-
tifiability problems of more complex modelling approaches, par-
ticularly in the context of limited experimental designs, also
supports our somewhat empirical modelling approach.33 A limita-
tion of the modelling work presented here is the empirical nature
of the time- and concentration-dependent decrease in drug effect
and hence we did not try to extrapolate beyond 24 h with our sim-
ulations, to answer questions such as optimal duration of therapy.
The drug combination effects have been parameterized as cat-
egorical covariates and resistance development in the cultures
was described using an empirical Gompertz equation. More com-
plex parameterizations to describe resistance development34 and
drug combination effects35 were tested although this did not re-
sult in statistically significant improved and/or robust models. This
was again in line with Jacobs et al.33 who showed that parameters
in mechanistic models developed using total cfu data from time–
kill experiments can be unidentifiable.
The model used has quantified the synergy observed between
colistin and fusidic acid against MDRAB (fusidic acid reduced EC50col
by 82.6%). Moreover, the model has quantified the decreased co-
listin effect in the colistin-resistant strain, AB205 (i.e. EC50col
was 65.2-fold higher), although fusidic acid was more potent
(i.e. 2.12-fold increase and #0.124-fold decrease in sfus and bfus,
respectively) (Table 2). AB12 displayed a decreased colistin/fusidic
acid combination resistance effect (Table 2).
Having shown synergy with our model, the simulation results
(Figure 3) highlight the caution required in translating in vitro find-
ings to the clinic. Whilst the addition of fusidic acid to a colistin regi-
men clearly does improve the probability of bactericidal activity
(.3 log10 cfu/mL decrease), the high protein binding of fusidic acid
does appear to limit this somewhat. A possible explanation might
be that the observed serum concentrations do not wholly predict
intracellular concentrations of fusidic acid. Lemaire et al.36 found
that intracellular concentrations of fusidic acid (in macrophages)
reached five times that of extracellular compartments and may
explain the greater in vivo activity of fusidic acid compared with
the observed serum concentrations. Additionally, it has been pro-
posed that gastrointestinal reflux plays a major role in the devel-
opment of ventilator-associated pneumonia (VAP), with the acidic
environment causing mucosal damage and neutralization of pul-
monary macrophages.37 This acidic environment, however, may
further drive the intracellular accumulation of fusidic acid,36 result-
ing in disproportionately greater antimicrobial effect than pre-
dicted by the model. Finally, in vitro approaches are unable to fully
incorporate the effect of host immune factors in response to
Table 2. Parameter estimates for the colistin and fusidic acid pharmaco-
dynamics model
Parameter Fixed effect (RSE)
hnet (h
#1) 1.87 (4.5)
hcfumax (cfu/mL) 9.41 (0.600)
hlag (h) 0.352 (14.4)
hEC50col (ng/mL) 9.86 (23.5)
proportional increase in hEC50col with AB205 65.2 (41.6)
hEmaxcol (h
#1) 39.5 (10.6)
hccol 0.855 (4.60)
hscol 0.177 (38.6)
hbcol 0.895 (1.10)
hEC50fus (ng/mL) 310 (43.9)
hEmaxfus (h
#1) 23.2 (6.30)
hcfus 0.776 (8.30)
hsfus 0.0102 (37.2)
proportional increase in hsfus with AB205 2.12 (48.6)
hbfus 0.895 (fixed)
proportional decrease in hbfus with AB205 #0.124 (22.3)
proportional decrease in hEC50col with fusidic acid #0.826 (1.20)
proportional decrease in hEC50col with fusidic
acid for AB205
#0.986 (0.200)
proportional increase in hEmaxfus with colistin 0.579 (52.2)
hscomb 1.44 (15.9)
hbcomb 0.895 (fixed)
proportional decrease in hbcomb with AB12 #0.0523 (22.6)
Residual variabilitygrowth model 0.129 (15.9)
Residual variabilitycol 2.8 (47.5)
Residual variabilityfus 0.698 (9.30)
Residual variabilitycomb 5.14 (8.8)
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infection.38 It remains possible that a sufficient reduction in
bacterial load, without the consequent replacement of the initial
susceptible population with a resistant or heteroresistant subpo-
pulation,39 even without evident bactericidal activity as defined by
guidelines, may result in a positive outcome with the cooperative
intervention of host immune factors. However, based on our
results it would seem that a triple combination with a yet-to-be-
defined third agent will be required to be sure of clinical effect.
Conclusions
The colistin/fusidic acid combination presents a novel approach
for the treatment of A. baumannii infection. Utilizing PKPD mod-
elling, we have illustrated the potency of this combination, and
our findings do appear to show that some benefit would be
derived from adding fusidic acid to a colistin regimen in a pa-
tient infected with A. baumannii. A dosing regimen of 9 MU
followed by 3 MU three times per day for intravenous colistime-
thate sodium, and a loading dose of 1500 mg followed by
750 mg three times per day for oral fusidic acid, will maximize
the potential benefit.
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